Q1 Earnings Estimate for ARCT Issued By Leerink Partnrs

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) – Analysts at Leerink Partnrs issued their Q1 2025 earnings per share estimates for shares of Arcturus Therapeutics in a research note issued on Wednesday, April 16th. Leerink Partnrs analyst L. Nsongo anticipates that the biotechnology company will post earnings of ($1.24) per share for the quarter. The consensus estimate for Arcturus Therapeutics’ current full-year earnings is ($2.22) per share. Leerink Partnrs also issued estimates for Arcturus Therapeutics’ Q2 2025 earnings at ($1.74) EPS, Q3 2025 earnings at ($1.74) EPS, Q4 2025 earnings at ($1.71) EPS and FY2025 earnings at ($6.42) EPS.

Arcturus Therapeutics (NASDAQ:ARCT) last issued its earnings results on Thursday, March 6th. The biotechnology company reported ($1.11) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.78). Arcturus Therapeutics had a negative return on equity of 22.39% and a negative net margin of 36.39%. The business had revenue of $22.77 million for the quarter, compared to analyst estimates of $44.64 million.

A number of other analysts have also recently weighed in on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Arcturus Therapeutics in a research note on Friday, March 7th. Wells Fargo & Company lowered their target price on Arcturus Therapeutics from $58.00 to $50.00 and set an “overweight” rating for the company in a report on Friday, March 7th. HC Wainwright reiterated a “buy” rating and issued a $60.00 target price on shares of Arcturus Therapeutics in a research report on Thursday, April 10th. Canaccord Genuity Group reduced their price target on Arcturus Therapeutics from $74.00 to $68.00 and set a “buy” rating on the stock in a report on Monday, March 10th. Finally, BTIG Research set a $48.00 price objective on shares of Arcturus Therapeutics and gave the company a “buy” rating in a report on Monday, March 10th. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Arcturus Therapeutics has a consensus rating of “Buy” and a consensus target price of $59.20.

Arcturus Therapeutics Price Performance

ARCT stock opened at $10.53 on Friday. The stock has a market cap of $285.57 million, a price-to-earnings ratio of -4.74 and a beta of 3.41. The company has a 50 day simple moving average of $13.26 and a 200 day simple moving average of $16.50. Arcturus Therapeutics has a 1 year low of $8.04 and a 1 year high of $45.00.

Hedge Funds Weigh In On Arcturus Therapeutics

A number of hedge funds have recently made changes to their positions in ARCT. Franklin Resources Inc. increased its position in Arcturus Therapeutics by 54.6% during the 3rd quarter. Franklin Resources Inc. now owns 103,936 shares of the biotechnology company’s stock valued at $2,412,000 after purchasing an additional 36,714 shares during the period. Empire Life Investments Inc. raised its stake in Arcturus Therapeutics by 85.5% during the fourth quarter. Empire Life Investments Inc. now owns 279,463 shares of the biotechnology company’s stock worth $4,742,000 after buying an additional 128,771 shares during the last quarter. Hennion & Walsh Asset Management Inc. lifted its holdings in Arcturus Therapeutics by 139.7% in the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 82,057 shares of the biotechnology company’s stock valued at $1,393,000 after buying an additional 47,824 shares during the period. Spire Wealth Management grew its holdings in Arcturus Therapeutics by 393.3% during the 4th quarter. Spire Wealth Management now owns 13,478 shares of the biotechnology company’s stock worth $229,000 after acquiring an additional 10,746 shares during the period. Finally, SG Americas Securities LLC raised its position in shares of Arcturus Therapeutics by 45.0% in the 4th quarter. SG Americas Securities LLC now owns 11,940 shares of the biotechnology company’s stock worth $203,000 after acquiring an additional 3,705 shares in the last quarter. 94.54% of the stock is currently owned by institutional investors.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.